Company Profile

Ceregene’s unique combination of proprietary position, research, product development, and clinical expertise will allow it to develop its growth factor treatments into a commercial reality for treating neurodegenerative disorders.

Ceregene, Inc. is a private, San Diego-based biotechnology company focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders using a proprietary gene delivery technology. Founded in 2001, Ceregene raised $10.5M in initial financing and another $32M in 2004. The company has a highly motivated and efficient team of about 30 employees led by a seasoned management team, Board of Directors, and Scientific Advisory Board.

In its short history, Ceregene has already brought gene therapy products for Alzheimer’s disease and Parkinson’s disease through pre-clinical development and into clinical trials. Ceregene also has research programs investigating therapies for other neurodegenerative disorders for which no effective treatment exists, such as amyotrophic lateral sclerosis (ALS), ocular diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and glaucoma, and Huntington’s disease.

Ceregene’s gene therapy vectors deliver naturally occurring neurotrophic factors that slow or halt the neurodegeneration that underlies neurological disorders. Ceregene designs its therapies to slow, halt or possibly reverse neuronal degeneration, as opposed to currently accepted methods that merely try to compensate for loss of function. Using Ceregene’s technology, only a single treatment will be necessary to provide long-term therapy to degenerating nerve cells.